WHR Group Releases Employee Relocation Benchmark Results

MILWAUKEE, Wis., May 25, 2021 (GLOBE NEWSWIRE) — WHR Group, Inc. (WHR), a leader in the global employee relocation industry, conducted a Global Mobility Benchmark study surveying some of the largest U.S. companies from a variety of industries. Findings shed light on how companies have changed their employee relocation policies, even during 2020 and a pandemic. Respondents included corporate staff working in HR, mobility management; talent management; and benefits and compensation departments. Some findings include the following:

  • Relocation benefits are still going strong even with the COVID–19 pandemic.
  • 85% of companies offer some type of home sale benefit to transferees.
  • 67% of respondents have experienced a talent shortage but include their mobility program in candidate recruitment strategies.
  • Lump sum benefits are trending but often used as a complement to basic relocation benefits versus a standalone benefit package.

Over 57% surveyed have an international relocation program, and 88% have expatriate or international permanent transfer policies. Over 50% found immigration laws to be the most challenging part of international relocations with Africa and Asia reported as the most challenging. For Africa, immigration laws and political climate were reported as creating the greatest challenges. For Asia, immigration laws and language barrier created the greatest challenges. Temporary housing; destination services and settling in; household goods; Visa and immigration assistance; and tax assistance are considered core benefits for international transfers and assignments.

Of the 68.5% offering destination closing costs, 76.5% don't cap this benefit, even though capping the support is a way to control organizational costs. Most companies reported creating benefit packages based on the average transferee, not always considering individual cultures and family dynamics. This can lead to policy exception requests by employees.

Download WHR's Complete Benchmark Report.

About WHR Group, Inc.
WHR is a privately owned, client–driven global employee relocation management company distinguished by best–in–class service delivery and cutting–edge, proprietary technology. WHR has offices in Milwaukee, Wis., Switzerland, and Singapore. With its 100% client retention rate for the past decade, WHR continues to position itself as the trusted provider in global employee relocation. http://www.whrg.com, LinkedIn, Twitter and Facebook.

Media Contact: Mindy Stroiman, Corporate Writer

GLOBENEWSWIRE (Distribution ID 8236127)

Blue California Opens New Possibilities in Functional Food and Beverages Following Dihydroquercetin (DHQ) GRAS Status

Rancho Santa Margarita, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Blue California's Taxifolin BC–DHQ with super antioxidant and anti–inflammatory properties is now Generally Recognized As Safe (GRAS) in a range of foods and beverages following a letter of no objection from the US Food and Drug Administration (FDA).

Naturally found in a variety of fruits and vegetables, Dihydroquercetin (DHQ), also known as taxifolin, is a flavonoid commonly found in apples, olive oil and red onions. As a flavonoid, taxifolin possesses powerful antioxidant and anti–inflammatory properties that may support immune health.

"This GRAS status is good news for consumers and brands alike, because it opens new doors for brands to create products that will excite health–conscious consumers," said Dr. Linda May–Zhang, research, science and innovation officer at Blue California. "DHQ is a powerful antioxidant that has a greater antioxidant capacity when compared to vitamin C, and it is ideal in a variety of on–trend food applications, including beverages, yogurt and chocolate products."

Health–conscious consumers are actively exploring new functional food and beverages for supporting immune health and wellness. Immune health will remain a top priority for consumers as 64% of global consumers are looking to improve their immunity over the next 12 months, reported by FMCG Gurus, Top Ten Trends for 2021, Dec. 2020.

DHQ seeks and neutralizes free radicals in the body, and its unique molecular structure makes it especially effective at preventing cellular damage. It can also play an important role in skin health since it protects cells and stimulates collagen and elastin production in the skin.

"Taxifolin BC–DHQ has much to offer as a powerful antioxidant in food and beverages as it provides improved color stability for beverages, extends shelf life, and enhances flavor," said May–Zhang. "Not only is DHQ regarded as a promising ingredient to immune health, it may also be used in cosmetic applications for anti–aging and UV–protection."

Blue California offers food and beverage manufacturers its high purity Taxifolin BC–DHQ made by a sustainable process. Innovation partner Conagen developed a clean, reliable, and scalable DHQ using its proprietary bioconversion process, resulting in a sustainable production method.

“Conagen is unlocking novel compounds from nature which are more sustainable and offer better options for ingredient applications, said Dr. Casey Lippmeier, vice president of innovation at Conagen. "Our ability to rapidly scale–up and commercialize this and other novel ingredient solutions demonstrates our strength as a strategic service partner."


Taxifolin BC–DHQ, is a registered trademark of Blue California, Inc.

About Blue California

Blue California is an entrepreneurial, science–based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural product and nature–inspired industries.

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop sustainable, nature–based molecules bio–manufactured into the highest quality products available. We focus on the bioproduction of high–value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com


GLOBENEWSWIRE (Distribution ID 8242564)

Anaqua Acquires Actio IP to Offer Integrated Tech-Enabled Foreign Filing Solutions

BOSTON, May 24, 2021 (GLOBE NEWSWIRE) — Anaqua, the leading innovation and intellectual property (IP) management technology provider, today announced that it has acquired tech–enabled IP services company Actio IP from Acapo AS. The transaction further strengthens Anaqua's strategic line of IP management solutions, offering corporations and law firms an intuitive, transparent, and efficient experience in managing the Patent Cooperation Treaty (PCT) National Phase and European Patent (EP) Validation filing processes.

Anaqua will continue to enhance Actio IP's tech–enabled foreign filing services platform, ACTIO Portal, while significantly investing in the integration of the services with Anaqua's IP management software and payment services. Actio IP, which also offers IP renewals, will add incremental volume to Anaqua's existing payments business.

"Both companies share a deep commitment to leveraging technology to optimize the IP workflow process," said Christine Jennings, President of Anaqua Services, who will lead the new business unit. "We believe this combination will enhance the customer experience by pairing our existing payments business with another high–quality service that can be seamlessly–integrated with our software platforms and other offerings."

All Actio IP employees will join Anaqua as part of the acquisition, as the business expands its current operations in Bergen, Norway under the management of Actio IP executives Spencer Vold–Burgess and Anders Osa–Svanberg, who will both report to Christine Jennings.

"The combination of the two companies will serve to address the growing demand for increased efficiency in global filings," said Spencer Vold–Burgess, who will join Anaqua as Director, Client Services. "Since our initial interactions with Anaqua, it has been clear that we share the same goals in providing unparalleled IP solutions and customer service to help our clients streamline IP management processes. Our team has been impressed with Anaqua's global scale and client base, and look forward to joining the Anaqua team and innovating to better serve this evolving industry."

"Anaqua will be a great partner for Actio IP going forward," said Hilde Vold–Burgess, Managing Partner of Acapo. "This acquisition will strengthen Actio IP's capacity to pursue strategic growth initiatives and continue delivering innovative solutions to the IP industry. We wish Actio IP and the team all the best under the Anaqua umbrella, and look forward to continuing using their services as they enter this next phase of scaling."

Latham & Watkins LLP and Wikborg Rein Advokatfirma AS served as legal counsel to Anaqua.

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services. Anaqua's AQX platform combines best practice workflows with big data analytics and tech–enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision–making, and streamline IP operations. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua's solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators in large and medium–sized companies use the platform for their IP management needs. The company's global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com, or on LinkedIn.

About Actio IP
Actio IP AS was founded in 2009 with the goal of developing Intellectual Property (IP) solutions to reduce costs and administration. Based in Norway, Actio IP is a team of patent and trademark professionals who understand the needs and complex demands of the IP industry, what is involved in developing and managing complex portfolios, and the importance of creating strong international relationships. The company provides administrative services for IP professionals via the ACTIO Portal. Through the portal, users access a one–stop global platform for streamlining global filings, validations and renewals. The portal provides a gateway to international top–tier IP firms, giving flexibility and providing cost and time savings. The ACTIO Portal is an advanced and automated platform. Combined with an experienced IP administration team, this simplifies customers' global IP filings, validations and renewals to free up time for higher–value tasks. For more information, visit actio.no, or on LinkedIn.

About Acapo
Acapo is one of the leading Intellectual Property consultancy firms in Norway with offices in Oslo, Bergen, Trondheim and Fredrikstad. The firm's services include advisory services within all fields of IPR. Filing and prosecution of applications for European and Norwegian patents is within Acapo's core field of business and their lawyers attend to litigation of cases pertaining to i.e. patents, trademarks and marketing law. The highly skilled staff of Acapo also handle filing of applications for Norwegian and European trademark and design registrations. As a full–service IPR–firm, Acapo also attend to maintenance of patents, and design and trademark registrations. For more information, visit acapo.no, or on LinkedIn.

Company Contact:
Amanda Hollis
Associate Director, Communications

GLOBENEWSWIRE (Distribution ID 8242076)

UD Trucks Assembled in the Kingdom Today For the Kingdom of Tomorrow

JEDDAH, Saudi Arabia, May 23, 2021 (GLOBE NEWSWIRE) — UD Trucks, the leading Japanese truck manufacturer, with a range of medium and heavy duty vehicles that provide comprehensive solutions that meet the needs of Kingdom's demanding transportation sector are now being assembled, with excellence, in the Kingdom of Saudi Arabia at Zahid Group's Arabian Vehicles & Trucks Industry (AVI) facility in the King Abdullah Economic City (KAEC).

AVI is now the only facility in the world that assembles Volvo Trucks, Renault Trucks and UD Trucks on the same production line; an achievement that showcases Zahid Tractor, AVI and Zahid Group's relentless commitment to creating career opportunities and enhancing the careers of Saudi Arabian nationals.

Commenting on this announcement, Mr. Nasser J. Bayram, Group President "" Transport at Zahid Group stated, “From the outset of our journey with UD Trucks, our main objective has been to ensure that UD Trucks joins the league of 'Made in Saudi'". Mr. Bayram added, "It has been a year since the brand's relaunch Saudi Arabia and we are very happy to see that we are delivering on our plan and our strategy; today we can finally say that UD has joined the league as the first trucks roll off the AVI assembly plant in KAEC.

Zahid Tractor Commercial Vehicles Division, is driving the Kingdom's manufacturing and transportation industries towards achieving Vision2030 and is committed to continuously investing in human resources and state–of–the–art technology along the way.

Mr. Mohamed W. Zahid, Director of Zahid Tractor's Commercial Vehicles Division added, "For the last forty–one years, we have proudly represented AB Volvo's truck brands in the Kingdom of Saudi Arabia and added UD Trucks to the existing portfolio of Volvo and Renault Trucks in January 2020. We have seen a significant interest and demand for UD Trucks. Through our kingdom wide network of branches, state–of–the–art facilities and our well trained and experienced team, UD truck owners across the kingdom are receiving the needed service, support and guidance." Mr. Zahid added, "Given the Japanese technology that differentiates UD Trucks, and considering our customer relationships that are based on professionalism, excellence and integrity, we are confident that the assembly of UD Trucks in the Kingdom of Saudi Arabia will spearhead the continued growth in demand for UD Trucks."

On behalf of UD Trucks, Mr. Mourad Hedna President of UD Trucks MEENA commented, "Saudi Arabia is and will continue to be one of the biggest and most important market for UD Trucks in the Middle East, East and North Africa region. With Zahid Tractor's professionalism and long experience in the trucking industry and with UD Trucks reputation and strong Japanese heritage based on quality and reliability, we are convinced that we will contribute to our customer's success. During the launch ceremonies held in February 2020 I promised that UD Trucks would soon be assembled in the Kingdom and here we are today, 12 months later, celebrating the assembly of the first UD Truck in Saudi Arabia!"


UD Trucks is a leading Japanese commercial vehicle solutions provider, active in more than 60 countries on all continents. Since its inception in 1935, the company has been an innovation leader with a clear vision to provide the trucks and services the world needs today. The company is committed to go the extra mile for smart logistics with the most dependable solutions for demanding customers. To best support across applications and geographies, UD Trucks offers a full range of heavy–duty trucks – Quon and Quester, medium duty trucks – Condor and Croner, and light duty trucks – Kazet and Kuzer, as well as associated operational and financial services.

UD Trucks is a proud member of the Volvo Group, which in 2018 saw a year–on–year increase in sales of nine percent and employs a workforce of 100,000 employees globally.

For more information from the UD Trucks, please visit: http://www.udtrucks.com/en–int/home

Zahid Tractor is a Zahid Group company. Zahid Group has successfully evolved over the course of the last century from its origins as a modest trading concern to become a multi–national organization encompassing a diverse portfolio of companies operating across 11 sectors.

The Group's success is built on long–standing partnerships, associations with globally renowned brands and its adherence to the highest levels of professionalism and operating standards.

For more information from Zahid Group, please visit: www.zahid.com

Contact info:
Ali Al Tarawneh

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e507e254–b46e–408b–b373–ecf678f3c26e

GLOBENEWSWIRE (Distribution ID 8240340)

PandoLogic Inc. Acquires Conversational AI Recruiting Provider Wade & Wendy

NEW YORK and HERZLIYA, Israel, May 20, 2021 (GLOBE NEWSWIRE) — PandoLogic, the world's leading provider of programmatic recruitment advertising, today announced its acquisition of conversational AI recruiting provider Wade & Wendy. The action positions PandoLogic as the only programmatic advertising provider that can define a quality applicant without the inherent bias that results from human intervention.

The acquisition will accelerate the adoption of programmatic job advertising as a best practice by combining PandoLogic's world–class performance with Wade & Wendy's AI power for candidate engagement and qualification to ensure delivery of the highest possible volume of only the most qualified applicants.

PandoLogic President and CEO Terry Baker said, “This acquisition reinforces our position as the most technologically advanced provider of AI–enabled recruitment automation software. We're delighted to welcome the Wade & Wendy team to PandoLogic and look forward to our great work together.”

PandoLogic's primary offering is pandoIQ, a programmatic job advertising platform. PandoIQ automates and optimizes job ad placements to help companies meet hiring needs by predicting optimal yields for recruitment advertising budgets. Making more than 7,000 micro–decisions per minute, pandoIQ eliminates inefficiencies and waste by reaching the right candidates for the right price on the right sites at the right time.

Adding Wade & Wendy's conversational AI to pandoIQ will deliver a more personalized application and candidate experience. Not only does Wade & Wendy automate the arduous process of scheduling candidate interviews, but it also intelligently transacts time–consuming tasks such as sourcing and screening.

Drew Austin, CEO and founder of Wade & Wendy, shared, “We entertained multiple offers and chose PandoLogic given our strong cultural fit and solid foundation from which to drive future growth. As hiring rebounds sharply, it's the perfect time for our companies to come together.”

Baker added, “As organizations shift more to remote and hybrid workplaces and diversity hiring escalates in importance, our digital–first, one source of truth approach ensures productive collaboration across teams. Our Hire Intelligence approach just got smarter with Wade & Wendy's AI–enabled contextual engagement for sourcing qualified candidates, and PandoLogic's strong strategic alignment with Wade & Wendy will give our mutual clients the best of both organizations under the PandoLogic brand.”

Madeline Laurano, founder of Aptitude Research, said, “We're entering one of the hottest job markets in over a decade, making the need to recruit intelligently and hire quickly crucial to organizational viability. Both PandoLogic and Wade & Wendy have consistently demonstrated their ability to drive measurable results for hiring companies and exemplary experiences for job candidates.”

Effective immediately, customers will be able to purchase Wade & Wendy and PandoLogic products independently or as a bundled offering. Other terms of the agreement are not being disclosed.

About Wade & Wendy
Wade & Wendy is an on–demand recruitment automation platform that increases recruiters' bandwidth to make for a better – and more human – candidate experience. Their AI recruiter platform automates task–driven recruitment processes: sourcing, screening and recommending qualified & interested candidates.

Founded in 2015, Wade & Wendy has raised $11.5M of funding from investors, including ff Venture Capital, Jazz Venture Partners, Indicator Ventures, Slack and the Randstad Innovation Fund.

About PandoLogic
PandoLogic is the leading programmatic job advertising and vendor management platform in North America. Referred to as the “best–kept secret in HR,” its programmatic job advertising platform, pandoIQ, automates and optimizes job ad placements to help companies meet hiring needs while maximizing recruitment ad spend. Evaluating 100T job data points and making 7,000 micro–decisions per minute, pandoIQ eliminates inefficiencies and waste by reaching the right candidates on the right sites at the right time for the right price via a single performance–based platform.

One vendor, one source of truth, better results. Learn more at pandologic.com.

GLOBENEWSWIRE (Distribution ID 8240406)

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

"' Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3–Month Primary Endpoint; Final Data Including BMD Expected Q2:21 "'

"' Entera's Oral Delivery Platform Shows Potential in Indications Including GLP–2 and Human Growth Hormone "'

"' Company to Host Conference Call and Webcast Today at 8:30 a.m. ET "'

BOSTON and JERUSALEM, May 20, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the quarter ended March 31, 2021.

First Quarter 2021 and Recent Highlights

  • 3–Month Primary Efficacy Endpoint Achieved in Phase 2 Trial of EB613 in Osteoporosis: EB613, an orally delivered human parathyroid hormone (1–34) or PTH, is positioned to be the first oral bone building (osteoanabolic) treatment for osteoporosis. The Phase 2 study's efficacy endpoints include an evaluation of biomarker data after 3 and 6 months of treatment and bone mineral density data (BMD) after 6 months of treatment. The study met its primary 3–month endpoint. Subjects in the 2.5 mg dose group had a significant (p<0.04) increase in bone formation biomarkers P1NP (primary endpoint) and Osteocalcin (p<0.006) from baseline compared to placebo. Patients in the 2.5 mg dose group also had a significant (p<0.015) reduction in CTX, a bone resorption marker correlated with a reduction in the breakdown of bone and an important factor for a potential increase in BMD. The last patient enrolled in the study has completed the last visit and final data analyses including 6–month BMD data are expected Q2 2021.

    Assuming positive final results from this trial, Entera intends to meet with the FDA to discuss the design of a pivotal Phase 3 non–inferiority trial examining the increase in spine bone mineral density of EB613 compared to the increase observed with Forteo (SC PTH 1–34) and confirm the potential for approval under the 505 (b)(2) regulatory pathway.

  • Positive Data from EB612 Phase 2a Clinical Trial in Hypoparathyroidism (HypoPT) Published: An article titled "Safety and Efficacy of Oral Human Parathyroid Hormone (1–34) in Hypoparathyroidism: An Open–Label Study" published in The Journal of Bone and Mineral Research Results reported results from Entera's Phase 2a clinical study which achieved its primary and secondary endpoints. Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin–adjusted calcium, and reduction of serum phosphate. The Company expects to initiate a Phase 2b HypoPT trial in 2022.
  • Oral Large Molecule Delivery Platform Shows Potential in GLP–2 and hGH: Based on positive pre–clinical data, Entera initiated a research program for an oral glucagon–like peptide–2 (GLP–2) analog which may support a new class of drugs to treat a broad range of gastrointestinal and metabolic diseases. Currently, the only GLP–2 analog on the market is a once–daily injection for the treatment of short bowel syndrome with reported global sales of $574 million in 2019. Showing efficacy in yet another indication, Entera delivered a poster presentation titled "Pharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice" at the 31st Annual European Pharma Congress in April. Plasma samples analyzed in the preclinical study showed substantial gastrointestinal absorption of Entera's oral hGH formulation and significant systemic exposure to the drug. Prescription hGH, a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications, a $3.7 billion market in 2020. Entera is currently evaluating different strategies to advance the oral GLP–2 and hGH programs into clinical development including through industry partnerships.
  • Robust Balance Sheet: Entera strengthened its balance sheet which currently has a cash position of over $16 million as of March 31, 2021 giving the Company an expected cash runway into the second quarter of 2022.

"We were very pleased with the 3–month efficacy data for EB613 in the treatment of osteoporosis and look forward to announcing final 6 month BMD data this quarter. Despite the challenges of COVID, I am grateful to the patients, investigators and team's focus to successfully executing the study. A safe and effective oral PTH alternative is expected to substantially increase patient compliance and participation, thereby expanding the treatment market and offering a higher quality of life for people living with osteoporosis," stated Entera CEO Spiros Jamas. "Having identified new indications in which our formulations are showing preclinical efficacy, we are expanding the value of our platform and assets."

Financial Results for the Quarter Ended March 31, 2021

Revenues for the quarter ended March 31, 2021 were $157,000 compared to $42,000 for the quarter ended March 31, 2020, with revenues in both years attributable to R&D services provided to Amgen. The cost of revenues for quarter ended March 31, 2021 and 2020 were $58,000 and $42,000 respectively and were comprised of salaries and related expenses in connection with the R&D services provided to Amgen.

Operating expenses were $2.5 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020. Entera's operating loss was $2.4 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020.

Research and development expenses were $1.2 million for the quarter ended March 31, 2021, compared to $1.6 million for the quarter ended March 31, 2020. The decreasewas primarily due to a decrease of $0.2 million in professional and consulting services expenses due to submission of the IND in 2020 and a decrease of $0.2 million in EB613 clinical trial related expenses, including materials and production costs.

General and administrative expenses were $1.3 million for the quarter ended March 31, 2021, compared to $1.3 million for the quarter ended March 31, 2020. The quarter ended March 31, 2021 saw a decrease of $0.2 million in professional fees which was offset by an increase of $0.1 million in legal fees and $0.1 million in insurance and investor relations expenses.

Net comprehensive loss was $9.5 million or $0.43 per ordinary share (basic and diluted) for the quarter ended March 31, 2021 compared to $2.9 million, or $0.16 per ordinary share (basic and diluted) for the quarter ended March 31, 2020. The change in net loss was primarily due to the increase in the fair value of the warrants classified as financial liability, due to an increase in our market share price.

As of March 31, 2021, Entera had cash and cash equivalents of $16.4 million, compared to $8.6 million as of December 31, 2020. The increase was primarily due to sales under our ATM facility with Canaccord Genuity LLC.

Entera expects an operating loss of approximately $13.0 million for the year ending December 31, 2021 and believes its current cash position will be sufficient to fund its operations into the second quarter of 2022.

The Company's Board of Directors has decided to accelerate the termination date of its outstanding warrants, upon satisfaction of the sale price condition and in accordance with the terms of the warrants.

Conference Call and Webcast Information

Entera's management will host a conference call on Thursday, May 20, 2021 at 8:30 a.m. EDT. A question–and–answer session will follow Entera's remarks. To participate on the live call, please dial (855) 547–3865 (US) or (409) 217–8787 (international) and provide the conference ID "8483793" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the complete 3–month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA's interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Annual Report on Form 20–F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.




Three months ended

March 31



U.S. dollars in thousands



















Loss from change in fair value of financial liabilities at fair value



Other financial income, net














U.S. dollars


Basic and Diluted




Basic and Diluted





(US$ in thousands)

March 31

December 31




Cash and cash equivalents



Accounts receivable and other current assets



Other current assets



Property and equipment, net



Other assets, net



Total assets



Accounts payable and other current liabilities



Warrants liabilities



Total current liabilities



Total non–current liabilities



Total shareholders' equity



Total liabilities and shareholders' equity



GLOBENEWSWIRE (Distribution ID 8239692)

Zoom Announces Zoom Events Platform for Virtual Experiences

SAN JOSE, Calif., May 19, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced Zoom Events, an all–in–one platform with the power to produce interactive and engaging virtual experiences, available this summer. Zoom Events combines the reliability and scalability of Zoom Meetings, Chat, and Video Webinars in one comprehensive solution for event organizers, with the ability to produce ticketed, live events for internal or external audiences of any size.

Zoom Events offers something for a variety of use cases "" from enabling large businesses to seamlessly manage and host internal events like all–hands and sales summits and external events like user conferences, to smaller businesses and entrepreneurs who have been using OnZoom to create, host, and monetize events including fitness and cooking classes, theatrical presentations, and more. As part of the launch of Zoom Events, OnZoom, currently in Beta, will be rebranded and folded into Zoom Events, and can be either private, or searched and explored publicly.

Zoom's recent global study, How Virtual Do We Want Our Future to Be?, surveyed people worldwide on the role of video communications in our daily lives as we look beyond the pandemic. In the US, 80 percent of respondents agreed that everything will continue to have a virtual element post–pandemic, with 52 percent of US respondents planning to enjoy events both in–person and virtually, reinforcing the need for an all–in–one solution that will create seamless hybrid/virtual event experiences.

Zoom Events Platform Benefits:

  • Build an event hub to easily manage and share events
  • Customizable ticketing and registration
  • Control access and billing from one portal
  • Host a variety of events – free or paid, one–time or series
  • Bring attendees together with integrated networking
  • Track event statistics like attendance, registration, revenue, and more
  • Events can be kept private or posted to our public directory for others to discover
  • Zoom Events can be used with an existing paid Zoom Meetings or Video Webinar license

"It's an exciting time to be at Zoom where the pace of innovation continues to accelerate," said Oded Gal, chief product officer at Zoom. "We know that people are looking for flexibility in how they attend events in the future. The hybrid model is here to stay, and Zoom Events is a perfect solution for our customers who are looking to produce and host customer, company, and public events with an easy, yet powerful solution. This is another way we're helping customers scale to meet consumer demands and the evolving virtual and hybrid landscape."

To learn more about Zoom Events, please visit Zoom Events website and read our recent blog.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Farshad Hashmatulla
Product PR Manager

GLOBENEWSWIRE (Distribution ID 8239403)

MEDIA ALERT: Ethiopian novelist and Booker Prize finalist, Maaza Mengiste to deliver 8th Annual Pluralism Lecture


WHAT: Maaza Mengiste, award–winning author of The Shadow King, will deliver the 8th Annual Pluralism Lecture via livestream on May 19, 2021, about approaching difficult history in ways that can promote belonging over division.
Co–presented by the Global Centre for Pluralism and the University of British Columbia, this year's lecture features an introduction by Princess Zahra Aga Khan, Global Centre for Pluralism Board Member, reflecting on how the pandemic has created an urgency for building respect, empathy, and a more equitable, just and prosperous future for all.
WHERE: Livestream can be viewed at: https://www.pluralism.ca/event/maaza–mengiste–8thannual–pluralism–lecture
WHEN: Wednesday, May 19, 2021
12:00 p.m. EDT
WHO: Ethiopian novelist and 2020 Booker Prize finalist, Maaza Mengiste
CONTACT: Calina Ellwand, Manager
Communications and Public Affairs
Global Centre for Pluralism
OPPORTUNITIES: Audience Q&A with Maaza Mengiste, hosted by Nahlah Ayed (CBC Ideas)
Media may submit questions in advance to media@pluralism.ca
Lecture videos, transcript, and images available upon request

Maaza Mengiste
Maaza Mengiste, a critically acclaimed novelist and essayist, examines the individual lives at stake during migration, war, and exile. She was born in Addis Ababa, Ethiopia, and lived in Nigeria and Kenya before moving to the United States. Mengiste's debut novel, Beneath the Lion's Gaze (2010), was named one of The Guardian's 10 Best Contemporary African Books. Her latest novel, The Shadow King (2019), was called "one of the most beautiful novels of the year" by National Public Radio and was a 2020 Booker Prize finalist. Winner of the 2020 Literature Award from the American Academy of Arts and Letters, Mengiste's honours include the Creative Capital Award, a Fulbright Scholarship, and fellowships from the National Endowment for the Arts and Puterbaugh Festival of International Literature & Culture.

Global Centre for Pluralism
The Global Centre for Pluralism, founded by His Highness the Aga Khan and the Government of Canada, works with policy leaders, educators and community builders around the world to amplify and implement the transformative power of pluralism.

University of British Columbia
The University of British Columbia is a global centre for research and teaching, consistently ranked among the top 20 public universities in the world. Since 1915, UBC's entrepreneurial spirit has embraced innovation and challenged the status quo. UBC encourages its students, staff and faculty to challenge convention, lead discovery and explore new ways of learning.

GLOBENEWSWIRE (Distribution ID 8239012)

Bombardier Announces Closing of Placement of 7.45% Notes Due 2034 and Announces Amendment and Extension of Certain Consent Solicitations

MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) (the "Corporation") today announced that it has completed the issuance and sale to an institutional accredited investor (the "Investor") of US$260,000,000 aggregate principal amount of Bombardier's 7.45% Senior Notes due 2034 (the "Additional Notes") at a purchase price of par. The Additional Notes are additional notes of the same series, and are on the same terms and conditions, as the 7.45% Senior Notes due 2034 (the "2034 Notes") currently outstanding under the indenture, originally dated as of April 21, 2004, governing the 2034 Notes (the "2034 Indenture"). Following this private placement, the aggregate principal amount outstanding under the 2034 Notes is US$510,000,000. The Corporation intends to use the net proceeds from this private placement for the repayment of a portion of the Corporation's outstanding indebtedness.

The Corporation also today announced that it has amended and supplemented the terms of the consent solicitations in respect of its 2034 Notes and its 7.35% Debentures due 2026 ("Canadian Notes"), as set forth in the Corporation's Notice of Extension and Amendment dated May 18, 2021 ("Notice of Amendment") to the Consent Solicitation Statement dated May 3, 2021 (as amended by the press releases dated May 12, 2021 and May 14, 2021, the "Consent Solicitation Statement" and, together with the Notice of Amendment, the "Supplemental Consent Solicitation Statement").

2034 Notes

In respect of the 2034 Notes, the Consent Solicitation (as defined in the Supplemental Consent Solicitation Statement) has been amended and supplemented in order to (i) remove the record date for participation in the 2034 Notes Consent Solicitation and (ii) extend the expiration date of the 2034 Notes Consent Solicitation to 5:00 p.m., New York City time, on May 21, 2021 (the "Extended Expiration Date").

The Company has obtained the Investor's consent in respect of the proposed amendments to the 2034 Indenture described in the Consent Solicitation Statement. The Investor, which is the beneficial owner of a majority of the principal amount of the 2034 Notes, has further agreed to give its affirmative consent in the 2034 Notes Consent Solicitation.

ALL CONSENTS PREVIOUSLY GIVEN IN THE CONSENT SOLICITATION WITH RESPECT TO THE 2034 NOTES ARE NO LONGER EFFECTIVE, AND ANY HOLDER OF 2034 NOTES WHO WISHES TO PROVIDE ITS CONSENT IN THIS CONSENT SOLICITATION MUST VALIDLY GIVE THEIR CONSENT ON OR AFTER MAY 18, 2021 AND ON OR PRIOR TO THE EXTENDED EXPIRATION DATE. For the avoidance of doubt, any holder of 2034 Notes who has previously consented to the Consent Solicitation with respect to the 2034 Notes must validly deliver their consent again in order to receive the Consent Payment (as defined in the Supplemental Consent Solicitation Statement). Consents may not be revoked once given, including during any extension of the Consent Solicitation period, except as provided in the Supplemental Consent Solicitation Statement.

Canadian Notes

Consent Solicitation in respect of the Canadian Notes has been extended such that the expiration date of the Consent Solicitation is the Extended Expiration Date (being 5:00 p.m., New York City time, on May 21, 2021).

All holders of the 2034 Notes or Canadian Notes whose consents are properly made and not revoked on or prior to the Extended Expiration Date will be entitled to receive the Consent Payment, subject to the terms and conditions set forth in the Supplemental Consent Solicitation Statement.

Except as set forth in the Supplemental Consent Solicitation Statement with respect to the removal of the record date in respect of the Consent Solicitation for the 2034 Notes and the extension of the expiration dates of the Consent Solicitations for the 2034 Notes and the Canadian Notes, the terms and conditions of the Consent Solicitations remain the same as set forth and described in the original Consent Solicitation Statement dated May 3, 2021 (as amended and extended). The Corporation reserves the absolute right, subject to applicable laws, to further amend, waive or modify the terms of the Consent Solicitations in any manner. For a complete statement of the terms and conditions of the Consent Solicitations, holders are encouraged to read the Supplemental Consent Solicitation Statement.

Holders are advised to check with any bank, securities broker or other intermediary through which they hold any of the notes as to when such intermediary needs to receive instructions from a holder in order for that holder to be able to participate in, or (in the circumstances in which revocation is permitted) revoke their instruction to participate in, the Consent Solicitations, before the deadlines specified herein and in the Supplemental Consent Solicitation Statement. The deadlines set by each clearing system for the submission and withdrawal of instructions will also be earlier than the relevant deadlines specified herein and in the Supplemental Consent Solicitation Statement. You should check with such broker, dealer, commercial bank, trust company or other nominee to determine whether they will charge you a fee for delivering your consent on your behalf.

For additional information regarding the terms of the Consent Solicitations, or to obtain additional copies of the Supplemental Consent Solicitation Statement, please contact Global Bondholder Services Corporation at (866) 807 2200 or by email at contact@gbsc–usa.com, or, in respect of the Canadian Notes, Kingsdale Partners LP at 1–888–518–6824 or by email at corpaction@kingsdaleadvisors.com. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Consent Solicitations.

Citigroup Global Markets Inc. and UBS Securities LLC are acting as the Solicitation Agents for the Consent Solicitations. Questions concerning the terms of the Consent Solicitations should be directed to Citigroup Global Markets Inc. at (212) 723–6106 (collect) or (800) 558–3745 (toll–free) or UBS Securities LLC at (203) 719–4210 (collect) or (888) 719–4210 (toll–free).

None of the Corporation, the trustees for the notes, the agents under the respective indentures for the notes, the information agents, any of their respective subsidiaries or affiliates or any of its or their respective directors, officers, employees or representatives makes any recommendation to holders as to whether or not to deliver their consent pursuant to any of the Consent Solicitations, and none of the foregoing has authorized any person to make any such recommendation. Holders must decide whether to provide their consent.

This notice does not constitute or form part of any offer or invitation to purchase, or any solicitation of any offer to sell, the notes or any other securities in the United States or any other jurisdiction, and neither this notice nor any part of it, nor the fact of its release, shall form the basis of, or be relied on or in connection with, any contract therefor. The Consent Solicitations are made only by and pursuant to the terms and conditions of the Supplemental Consent Solicitation Statement and the information in this notice is qualified by reference to the Supplemental Consent Solicitation Statement.

This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful.

The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or in a transaction exempt from or not subject to such registration requirements. The securities mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada must be made on a basis which is exempt from the prospectus requirements of such securities laws.

Holders are requested to read and consider carefully the information contained in the Supplemental Consent Solicitation Statement and to deliver their consent in accordance with the instructions set forth in the Supplemental Consent Solicitation Statement.

About Bombardier

Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of more than 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a trademark of Bombardier Inc. or its subsidiaries.

This announcement does not constitute an offer to buy or the solicitation of an offer to sell any securities in any jurisdiction or in any circumstances in which such offer or solicitation is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Consent Solicitations to be made by a licensed broker or dealer, the Consent Solicitations will be deemed to be made by one or more registered brokers or dealers licensed under the laws of such jurisdiction.

Certain statements in this announcement are forward–looking statements based on current expectations. By their nature, forward–looking statements, including statements with respect to the Corporation's ability to complete the Consent Solicitations, are based on estimates, projections, beliefs and assumptions that Bombardier believes are reasonable but are not guarantees of future events and results.

Forward–looking statements require us to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from those set forth in the forward–looking statements. For additional information regarding these risks and uncertainties, and the assumptions underlying the forward–looking statements, please refer to the Supplemental Consent Solicitation Statement.

For information

Francis Richer de La Flche
Vice President, Financial Planning
and Investor Relations
+514 855 5001 x13228
Mark Masluch
Senior Director, Communications
+514 855 7167

GLOBENEWSWIRE (Distribution ID 8238541)

Bombardier Collaborates with Sterling for Enhanced Worldwide Customer Support of Parts Shipments

  • Fully integrated solution for parts delivery further bolsters responsiveness and complements Bombardier's extensive parts network
  • Bombardier can now access a network of aircraft for parts dispatch to customers worldwide

  • Enhanced parts delivery capability complements Bombardier's rapidly growing customer service network, which is currently expanding by more than 50%

MONTRÉAL, May 18, 2021 (GLOBE NEWSWIRE) — Bombardier today announced its collaboration with Sterling Global Aviation Logistics, a global leader in aviation transportation and logistics to enhance worldwide dispatch of parts for its customers. The collaboration provides Bombardier with access to a network of aircraft, based across five continents, with which to deliver a wide variety of parts to customers quickly and efficiently in the event of an aircraft on ground (AOG) situation.

"Our customers deserve fast and effortless AOG resolution and our collaboration with Sterling, an industry leader in providing AOG Logistics around the globe, allows us to quickly and efficiently deliver the parts our customers need," said Andy Nureddin, Vice President, Customer Support, Bombardier. "We are delighted to further enhance our portfolio of solutions, and we are proud to add this offering to the ways in which we can be there for our customers when and where they need us."

"We are very excited to provide global logistics support to Bombardier's enhanced parts delivery solutions for their customers and are proud of our long–standing strategic collaboration of over 15 years," said Robert Broderick, Executive Vice President, Sterling Global Aviation Logistics.

Bombardier customers can fly with confidence knowing that they have the backing of one of the industry's most expansive parts distribution networks with parts facilities located across North America, Europe, Asia, and the Middle East. Shipping more than 350,000 parts annually with an impressive network–wide parts availability rate of 96%, Bombardier's sophisticated inventory management system maximizes parts availability, shipping and tracking 24/7. Customers who buy parts from Bombardier can continue to benefit from a two–year parts warranty guarantee and price matching.

The enhanced parts delivery service is one of many solutions available to customers in need of immediate assistance. Bombardier's Mobile Response Team boasts world–class AOG coverage with 30 mobile response team trucks worldwide. Additionally, customers can count on Bombardier for support of structural repairs for its leading family of Learjet, Challenger and Global aircraft. These high–quality repair solutions are available at one single point of contact through Bombardier's Customer Response Centre (CRC) at +1–866–538–1247 (North America) and +1–514–855–2999 (outside of North America).

The cross–functional CRC teams at Bombardier are also empowered with state–of–the art tools and technology and are backed by Bombardier's aircraft engineering expertise. Bombardier continues to reinforce its ongoing commitment to providing its customers with the most comprehensive onsite, mobile and aircraft–on–ground resolution services in the industry.

This announcement is the latest in a series aimed at enhancing Bombardier's worldwide customer service network and increasing its infrastructure footprint by 50%. These include the expansion of Bombardier's service centre network in Berlin, Miami, Biggin Hill, London, Singapore and the new service centre to be built in Melbourne, Australia; new Line Maintenance Stations (LMS) at strategic locations in the U.S, Europe; as well as new products and services for customers, including the next steps in Bombardier's digital transformation.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

About Sterling Global Aviation Logistics
Since 1981, Sterling Global Aviation Logistics, a Kuehne and Nagel company, has been helping aviation clients with their worldwide priority shipping, transporting valuable aircraft parts swiftly and efficiently. Sterling specializes in shipping AOG aircraft parts, heavy weight or oversized freight, and dangerous goods, while keeping down time to a minimum. With a focus on providing global AOG Logistics, Sterling is at the forefront of innovations, offering precision, individualized service and dependability.

More information is available at www.sterlingaog.aero.

Bombardier, Learjet, Challenger, and Global are registered or unregistered trademark of Bombardier Inc. or its subsidiaries.

For Information
Matthew Nicholls

For Information
Marie Vigliarolo
Sterling Global Aviation Logistics
+1–718–995–3616 ext. 2207

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/25b1ad57–3fc7–4617–b4fb–8d0997db07b3

GLOBENEWSWIRE (Distribution ID 8238537)